 |
 Video: What is a Stock Split?
|
|
|
| Black Diamond Therapeutics is an oncology medicine company focusing on the discovery and development of small molecule, MasterKey therapies. Co.'s proprietary technology platform, which it refers to as its Mutation-Allostery-Pharmacology drug discovery engine, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Co. has designed its clinical-stage product candidates, BDTX-1535 and BDTX-189, to selectively inhibit families of oncogenic mutations which occur across a range of tumor types that affect the ErbB-1 epidermal growth factor receptor. According to our Black Diamond Therapeutics stock split history records, Black Diamond Therapeutics has had 0 splits. | |
|
Black Diamond Therapeutics (BDTX) has 0 splits in our Black Diamond Therapeutics stock split history database.
Looking at the Black Diamond Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Black Diamond Therapeutics shares, starting with a $10,000 purchase of BDTX, presented on a split-history-adjusted basis factoring in the complete Black Diamond Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/03/2020 |
|
| End date: |
04/18/2024 |
|
| Start price/share: |
$38.00 |
|
| End price/share: |
$5.30 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-86.05% |
|
| Average Annual Total Return: |
-37.40% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,394.75 |
|
| Years: |
4.21 |
|
|
|
|
|
